Mekaoui L

GHU Paris Psychiatrie et Neurosciences, Hôpital Sainte-Anne, CMME,

8 papers · 1 preprint · ORCID

ArticleKetamine

Esketamine-induced dentate gyrus plasticity in treatment resistant depression: first-in-human evidence

Berre, Attali D, Uszynski I +16

Europe PMC2026
PreprintKetamine

Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study

Mallevays M, Fuet L, Danon M +15

Europe PMC2026
ArticleKetamine

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.

Rothärmel M, Mekaoui L, Kazour F +21

Europe PMC2026
ArticleKetamine

Effectiveness and factors associated with esketamine response during the 4-week induction period for treatment-resistant depression: post-hoc analysis of the real-world ESKALE study.

Samalin L, Rothärmel M, Mekaoui L +6

Europe PMC2026
ArticleKetamine

Is there an independant anti-suicidal effect of esketamine in treatment resistant depression?

Danon M, Ostronoff G, Petit AC +5

Europe PMC2026
ArticleKetamine

Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study.

Samalin L, Mekaoui L, Rothärmel M +5

Europe PMC2024
ArticleKetamine

Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray.

Samalin L, Mekaoui L, De Maricourt P +5

Europe PMC2024
ArticleKetamine

Early effects predict trajectories of response to esketamine in treatment-resistant depression.

Estrade I, Petit AC, Sylvestre V +11

Europe PMC2023
ArticleKetamine

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France

Wattinne E, Mekaoui L, Rothärmel M +2

Europe PMC2021